Correction: Microglial 5-LOX-activating protein antagonism alleviates leukotriene-driven neuroinflammation - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Inhibition of Microglial 5-LOX-Activating Protein Mitigates Neuroinflammation Induced by Leukotrienes

  • By

  • Julia Konings

  • Fleur Mingneau

  • Serhii Chornyi

  • Cathrin E. Hansen

  • Rianne T. M. van der Burgt

  • Tessa G. van Elk

  • Laura Bolkaerts

  • Bo Batens

  • Gábor Tóth

  • Ingela Lanekoff

  • Frédéric M. Vaz

  • Alessio Cardilli

  • Marie Sels

  • Susanne M. A. van der Pol

  • Helga E. de Vries

  • Martin Giera

  • Oliver Werz

  • Sofie Kessels

  • Sanne G. S. Verberk

  • Jeroen F. J. Bogie

  • Merel Rijnsburger

  • Jerome J. A. Hendriks

  • Gijs Kooij

  • September 4, 2026

Share

Correction: Inhibition of Microglial 5-LOX-Activating Protein Mitigates Neuroinflammation Induced by Leukotrienes

Background

Neuroinflammation is a critical factor in various neurological disorders, particularly in the context of perioperative neurocognitive disorders among the elderly. Understanding the mechanisms behind microglial activation and polarization is essential.

Data Highlights

The article has undergone correction regarding the authorship, with the correct name being Rianne T. M. van der Burgt.

Key Findings

  • The original article incorrectly presented the author's name.
  • The corrected name is Rianne T. M. van der Burgt.
  • Neuroinflammation mediated by M1 microglia is a significant pathological mechanism in postoperative complications.
  • Neuron-derived exosomes may modulate microglial polarization.
  • Recent studies have linked leukotriene signaling to microglia-driven neuroinflammation.

Clinical Implications

Accurate authorship is essential for the integrity of scientific literature.

Conclusion

The correction of the author's name is crucial for proper attribution in scientific discourse.

Related Resources & Content

  1. Acta Neuropathologica, 2026 -- Correction: Inhibition of Microglial 5-LOX-Activating Protein Mitigates Neuroinflammation Induced by Leukotrienes
  2. Frontiers in Neurology — Neuronal exosomal miR-25-3p attenuates M1 microglial activation and neurotoxicity by targeting TLR4 to regulate the NF-κB signaling pathway
  3. Frontiers in Immunology — Calibrating microglia states in Alzheimer’s disease: decoding immune-metabolic networks and nano-targeted multicomponent therapies
  4. Frontiers in Immunology — Cholinergic regulation of neuroinflammation: linking microglia, immunometabolism, and neuromodulation
  5. Acta Neuropathologica — The Role of Microglia and Monocytes in CNS Inflammatory Disorders: A Focus on Their Phenotypic and Functional Integration
  6. Microglial 5-LOX-activating protein antagonism alleviates leukotriene-driven neuroinflammation - PMC
  7. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup - PMC
  8. Study Details | NCT03991988 | Montelukast Therapy on Alzheimer's Disease | ClinicalTrials.gov

Original Source(s)

Correction: Microglial 5-LOX-activating protein antagonism alleviates leukotriene-driven neuroinflammation

  • by Julia Konings, Fleur Mingneau, Serhii Chornyi, Cathrin E. Hansen, Rianne T. M. van der Burgt, Tessa G. van Elk, Laura Bolkaerts, Bo Batens, Gábor Tóth, Ingela Lanekoff, Frédéric M. Vaz, Alessio Cardilli, Marie Sels, Susanne M. A. van der Pol, Helga E. de Vries, Martin Giera, Oliver Werz, Sofie Kessels, Sanne G. S. Verberk, Jeroen F. J. Bogie, Merel Rijnsburger, Jerome J. A. Hendriks, Gijs Kooij

  • September 4, 2026

Related Content

Paucibacillary tuberculous meningitis with clinical-radiological dissociation: A diagnostic challenge

FDA approves first therapy for Alexander disease

The antisense oligonucleotide reduces production of the abnormal protein that accumulates in supportive cells in the brain.

Short-term postoperative neurocognitive safety and recovery profiles of remimazolam tosilate combined with flumazenil vs. propofol in cirrhotic patients undergoing endoscopic variceal treatment: a randomized controlled trial